{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "33ae4235",
   "metadata": {},
   "source": [
    "### Select a sample of biotech and pharma public companies\n",
    "\n",
    "| Ticker | Company Name               | Platform / Focus                                            | Development Stage                                                      |\n",
    "|:------:|---------------------------|-------------------------------------------------------------|-------------------------------------------------------------------------|\n",
    "| VERV   | Verve Therapeutics         | Base editing (in vivo CRISPR) targeting PCSK9/Lipoproteins | Early clinical (Phase 1b “Heart-2”); Fast Track; lead candidate VERVE‑102 |\n",
    "| NTLA   | Intellia Therapeutics      | CRISPR/Cas9 — both in vivo (liver, ATTR/HAE) & ex vivo cell editing | Clinical-stage: Phase 1/2 for ATTR and HAE; recently dosed Phase 3 patient |\n",
    "| EDIT   | Editas Medicine           | CRISPR/Cas9 & Cas12a for in vivo (HSC, liver) and ex vivo applications | Preclinical & early clinical—proof-of-concept in vivo data presented |\n",
    "| BIIB   | Biogen                     | Neurology & rare disease biologics (MS, ALS, spinal muscular atrophy) | Late-stage clinical and commercial; multiple Phase 2/3 neuroimmunology candidates |"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "id": "22f2810a",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import re\n",
    "import json\n",
    "import requests\n",
    "import pandas as pd\n",
    "from typing import Dict, List\n",
    "from datetime import datetime\n",
    "from collections import defaultdict\n",
    "\n",
    "# Load API Key\n",
    "CAPTIDE_API_KEY = os.getenv(\"CAPTIDE_API_KEY\")\n",
    "\n",
    "# Set headers\n",
    "HEADERS = {\n",
    "    \"X-API-Key\": CAPTIDE_API_KEY,\n",
    "    \"Content-Type\": \"application/json\",\n",
    "    \"Accept\": \"application/json\"\n",
    "}\n",
    "\n",
    "# Define tickers and cutoff date\n",
    "TICKERS = [\"VERV\", \"NTLA\", \"EDIT\", \"BIIB\"]\n",
    "cutoff_date = \"2022-12-31\""
   ]
  },
  {
   "cell_type": "markdown",
   "id": "316bd2ff",
   "metadata": {},
   "source": [
    "### Select Relevant Documents\n",
    "\n",
    "| Event Type                             | Typical 8-K Item | Notes                                           |\n",
    "|---------------------------------------|------------------|-------------------------------------------------|\n",
    "| Clinical trial results (early or final) | 7.01 or 8.01     | Often voluntary under FD or Other Events        |\n",
    "| FDA approval or rejection              | 7.01 or 8.01     | BLA/NDA/IND status updates                      |\n",
    "| Clinical hold or warning letter        | 8.01             | Sometimes also 7.01 if disclosed widely         |\n",
    "| Program discontinuation                | 8.01 or 2.05     | 2.05 if cost-related                            |\n",
    "| New collaboration or licensing deal    | 1.01             | Often with financial terms                      |\n",
    "| Termination of a partnership/license   | 1.02             | Could signal clinical failure                   |"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "id": "12503aa3",
   "metadata": {},
   "outputs": [],
   "source": [
    "def is_valid_document(doc: Dict) -> bool:\n",
    "    if doc[\"sourceType\"] == \"8-K\":\n",
    "        item_str = doc.get(\"additionalKwargs\", {}).get(\"item\", \"\")\n",
    "        relevant_items = {\"1.01\", \"1.02\", \"2.05\", \"7.01\", \"8.01\"}\n",
    "        return any(item in item_str for item in relevant_items)\n",
    "    return True\n",
    "\n",
    "def parse_sse_response(sse_text: str) -> Dict:\n",
    "    try:\n",
    "        lines = [l[6:] for l in sse_text.splitlines() if l.startswith(\"data: \")]\n",
    "        for l in lines:\n",
    "            obj = json.loads(l)\n",
    "            if obj.get(\"type\") == \"full_answer\":\n",
    "                content = re.sub(r\"\\s*\\[#\\w+\\]\", \"\", obj[\"content\"])\n",
    "                m = re.search(r\"\\{.*\\}\", content, re.DOTALL)\n",
    "                return json.loads(m.group(0)) if m else {}\n",
    "    except Exception:\n",
    "        pass\n",
    "    return {}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "id": "610e0daf",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Fetched 30 raw documents for VERV\n",
      "[\n",
      "  {\n",
      "    \"ticker\": \"VERV\",\n",
      "    \"sourceLink\": \"https://rest-api.captide.co/api/v1/document?sourceType=8-K&documentId=6eff02cb-497d-466c-bf9e-54f5e29b2777\",\n",
      "    \"date\": \"2025-06-17\"\n",
      "  },\n",
      "  {\n",
      "    \"ticker\": \"VERV\",\n",
      "    \"sourceLink\": \"https://rest-api.captide.co/api/v1/document?sourceType=8-K&documentId=0a60ebbd-f8cb-4d1b-a95f-d132e83d4a2d\",\n",
      "    \"date\": \"2025-06-17\"\n",
      "  },\n",
      "  {\n",
      "    \"ticker\": \"VERV\",\n",
      "    \"sourceLink\": \"https://rest-api.captide.co/api/v1/document?sourceType=8-K&documentId=59e6ea4b-3806-4d72-8c2b-a0cd2dd8db51\",\n",
      "    \"date\": \"2025-06-17\"\n",
      "  },\n",
      "  {\n",
      "    \"ticker\": \"VERV\",\n",
      "    \"sourceLink\": \"https://rest-api.captide.co/api/v1/document?sourceType=8-K&documentId=32f5d6ca-c90a-4f7b-b45d-2698c16d5479\",\n",
      "    \"date\": \"2025-06-17\"\n",
      "  },\n",
      "  {\n",
      "    \"ticker\": \"VERV\",\n",
      "    \"sourceLink\": \"https://rest-api.captide.co/api/v1/document?sourceType=8-K&documentId=42e15405-bf9a-407b-add4-f734c77588d4\",\n",
      "    \"date\": \"2025-06-17\"\n",
      "  },\n",
      "  {\n",
      "    \"ticker\": \"VERV\",\n",
      "    \"sourceLink\": \"https://rest-api.captide.co/api/v1/document?sourceType=8-K&documentId=64958827-d74f-4646-bf3e-b4d249d9a69c\",\n",
      "    \"date\": \"2023-11-29\"\n",
      "  },\n",
      "  {\n",
      "    \"ticker\": \"VERV\",\n",
      "    \"sourceLink\": \"https://rest-api.captide.co/api/v1/document?sourceType=8-K&documentId=31f14fa6-9d2a-4078-8cab-c8501773fb04\",\n",
      "    \"date\": \"2023-11-29\"\n",
      "  },\n",
      "  {\n",
      "    \"ticker\": \"VERV\",\n",
      "    \"sourceLink\": \"https://rest-api.captide.co/api/v1/document?sourceType=8-K&documentId=958ae7d4-6fea-4f95-b50c-5bec0a827792\",\n",
      "    \"date\": \"2023-11-29\"\n",
      "  }\n",
      "]\n"
     ]
    }
   ],
   "source": [
    "def fetch_documents(ticker: str) -> List[Dict]:\n",
    "    url = f\"https://rest-api.captide.co/api/v1/companies/ticker/{ticker}/documents?startDate={cutoff_date}\"\n",
    "    response = requests.get(url, headers=HEADERS, timeout=60)\n",
    "    docs = response.json()\n",
    "    print(f\"Fetched {len(docs)} raw documents for {ticker}\")\n",
    "    return [\n",
    "        {\n",
    "            \"ticker\": doc[\"ticker\"],\n",
    "            \"sourceLink\": doc[\"sourceLink\"],\n",
    "            \"date\": doc[\"date\"]\n",
    "        }\n",
    "        for doc in docs\n",
    "        if doc[\"sourceType\"] == \"8-K\"\n",
    "        and \"fiscalPeriod\" in doc\n",
    "        and is_valid_document(doc)\n",
    "    ]\n",
    "\n",
    "# Example:\n",
    "test_docs = fetch_documents(\"VERV\")\n",
    "print(json.dumps(test_docs, indent=2))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "id": "283b5e2c",
   "metadata": {},
   "outputs": [],
   "source": [
    "def fetch_metrics_with_prompt(source_links: List[str], prompt: str) -> Dict:\n",
    "    payload = {\"query\": prompt, \"sourceLink\": source_links}\n",
    "    r = requests.post(\n",
    "        \"https://rest-api.captide.co/api/v1/rag/agent-query-stream\",\n",
    "        json=payload, headers=HEADERS, timeout=120\n",
    "    )\n",
    "    return parse_sse_response(r.text)\n",
    "\n",
    "BASE_PROMPT = (\n",
    "    \"\"\"\n",
    "    Return a single valid JSON object with the following key-value pairs. Note that \"eventType\" dictates the required structure of the \"eventDetails\" field:\n",
    "\n",
    "    - \"eventType\": one of the following values — \"clinical_results\", \"fda_decision\", \"clinical_hold\", \"program_termination\", or \"program_announcement\".\n",
    "\n",
    "    - \"eventDetails\": an object containing structured details relevant to the specified \"eventType\", using the required fields listed below.\n",
    "\n",
    "    If the document does **not** contain any material information matching these event types, return:\n",
    "    {\n",
    "    \"eventType\": null,\n",
    "    \"eventDetails\": {}\n",
    "    }\n",
    "\n",
    "    Required fields per event type:\n",
    "\n",
    "    - If \"eventType\" = \"clinical_results\":\n",
    "    - \"trialPhase\" — e.g., Phase 1/2/3\n",
    "    - \"drugName\" — name of the investigational therapy\n",
    "    - \"indication\" — disease or condition being treated\n",
    "    - \"resultsSummary\" — concise summary of efficacy outcomes\n",
    "    - \"safetyProfile\" — any adverse events or tolerability findings\n",
    "    - \"nextSteps\" — upcoming plans (e.g., advancing to next phase)\n",
    "\n",
    "    - If \"eventType\" = \"fda_decision\":\n",
    "    - \"decisionType\" — e.g., approved, Complete Response Letter (CRL), delayed\n",
    "    - \"applicationType\" — e.g., NDA (New Drug Application), BLA (Biologics License Application)\n",
    "    - \"drugName\" — name of the drug reviewed\n",
    "    - \"indication\" — condition the drug is intended to treat\n",
    "    - \"notes\" — relevant regulatory context, labeling info, or committee outcomes\n",
    "\n",
    "    - If \"eventType\" = \"clinical_hold\":\n",
    "    - \"holdType\" — full or partial hold\n",
    "    - \"reason\" — FDA's stated rationale for the hold\n",
    "    - \"drugName\" — drug or program affected\n",
    "    - \"impactSummary\" — brief on trial or pipeline impact\n",
    "    - \"resolutionPlan\" — company's steps to address the hold\n",
    "\n",
    "    - If \"eventType\" = \"program_termination\":\n",
    "    - \"programName\" — name of the discontinued program\n",
    "    - \"indication\" — target disease area\n",
    "    - \"developmentStage\" — how far along the program was (e.g., preclinical, Phase 2)\n",
    "    - \"reason\" — scientific, strategic, or commercial rationale for termination\n",
    "    - \"financialImpact\" — expected cost savings or write-downs\n",
    "    - \"strategicNotes\" — effect on company direction or pipeline focus\n",
    "\n",
    "    - If \"eventType\" = \"program_announcement\":\n",
    "    - \"programName\" — name of the new or updated program\n",
    "    - \"indication\" — disease or condition being targeted\n",
    "    - \"platform\" — underlying technology (e.g., CRISPR, base editing)\n",
    "    - \"developmentStage\" — current status (e.g., preclinical, IND-enabling)\n",
    "    - \"milestone\" — key progress point announced (e.g., IND submission, trial start)\n",
    "    - \"partnershipInfo\" — details of any collaborations or licensing\n",
    "    - \"timelineEstimate\" — estimated timing of next milestone\n",
    "    \"\"\"\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "id": "23e20f0c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Fetched 30 raw documents for VERV\n",
      "Fetched 50 raw documents for NTLA\n",
      "Fetched 48 raw documents for EDIT\n",
      "Fetched 48 raw documents for BIIB\n"
     ]
    }
   ],
   "source": [
    "from concurrent.futures import ThreadPoolExecutor, as_completed\n",
    "\n",
    "def process_ticker(ticker: str):\n",
    "    try:\n",
    "        documents = fetch_documents(ticker)\n",
    "        table_data = defaultdict(lambda: defaultdict(str))  # eventType -> year -> detail\n",
    "        for doc in documents:\n",
    "            year = datetime.strptime(doc[\"date\"], \"%Y-%m-%d\").year\n",
    "            parsed = fetch_metrics_with_prompt([doc[\"sourceLink\"]], BASE_PROMPT)\n",
    "            event_type = parsed.get(\"eventType\")\n",
    "            if event_type:\n",
    "                full_event = {\"eventType\": event_type, \"eventDetails\": parsed[\"eventDetails\"]}\n",
    "                table_data[event_type][year] += json.dumps(full_event) + \"\\n---\\n\"\n",
    "        if table_data:\n",
    "            df = pd.DataFrame(table_data).T\n",
    "            return ticker, df\n",
    "        else:\n",
    "            return ticker, None\n",
    "    except Exception as e:\n",
    "        return ticker, None\n",
    "\n",
    "results_by_ticker = {}\n",
    "\n",
    "with ThreadPoolExecutor(max_workers=5) as executor:\n",
    "    futures = {executor.submit(process_ticker, ticker): ticker for ticker in TICKERS}\n",
    "    for future in as_completed(futures):\n",
    "        ticker, df = future.result()\n",
    "        if df is not None:\n",
    "            results_by_ticker[ticker] = df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "id": "4b491638",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "📢 Ticker: VERV\n",
      "\n",
      "🗂️ VERV — program_announcement — 2025\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<style type=\"text/css\">\n",
       "#T_86249_row0_col0, #T_86249_row1_col0, #T_86249_row2_col0, #T_86249_row3_col0, #T_86249_row4_col0, #T_86249_row5_col0, #T_86249_row6_col0 {\n",
       "  white-space: pre-wrap;\n",
       "}\n",
       "</style>\n",
       "<table id=\"T_86249\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th class=\"blank level0\" >&nbsp;</th>\n",
       "      <th id=\"T_86249_level0_col0\" class=\"col_heading level0 col0\" >Value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th id=\"T_86249_level0_row0\" class=\"row_heading level0 row0\" >Program Name</th>\n",
       "      <td id=\"T_86249_row0_col0\" class=\"data row0 col0\" >VERVE-102</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_86249_level0_row1\" class=\"row_heading level0 row1\" >Indication</th>\n",
       "      <td id=\"T_86249_row1_col0\" class=\"data row1 col0\" >Atherosclerotic cardiovascular disease (ASCVD), including heterozygous familial hypercholesterolemia (HeFH) and certain patients with premature coronary artery disease (CAD)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_86249_level0_row2\" class=\"row_heading level0 row2\" >Platform</th>\n",
       "      <td id=\"T_86249_row2_col0\" class=\"data row2 col0\" >In vivo gene editing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_86249_level0_row3\" class=\"row_heading level0 row3\" >Development Stage</th>\n",
       "      <td id=\"T_86249_row3_col0\" class=\"data row3 col0\" >Phase 1b clinical trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_86249_level0_row4\" class=\"row_heading level0 row4\" >Milestone</th>\n",
       "      <td id=\"T_86249_row4_col0\" class=\"data row4 col0\" >Granted Fast Track designation by the U.S. Food and Drug Administration; ongoing Phase 1b clinical trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_86249_level0_row5\" class=\"row_heading level0 row5\" >Partnership Info</th>\n",
       "      <td id=\"T_86249_row5_col0\" class=\"data row5 col0\" >Verve Therapeutics to be acquired by Eli Lilly and Company, with Lilly to accelerate development and commercialization of Verve's gene editing programs</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_86249_level0_row6\" class=\"row_heading level0 row6\" >Timeline Estimate</th>\n",
       "      <td id=\"T_86249_row6_col0\" class=\"data row6 col0\" >Transaction expected to close in Q3 2025; contingent value right (CVR) payable upon first patient dosed with VERVE-102 in a U.S. Phase 3 clinical trial within ten years of closing</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n"
      ],
      "text/plain": [
       "<pandas.io.formats.style.Styler at 0x159b08590>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "📢 Ticker: BIIB\n",
      "\n",
      "🗂️ BIIB — fda_decision — 2023\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<style type=\"text/css\">\n",
       "#T_0c53e_row0_col0, #T_0c53e_row1_col0, #T_0c53e_row2_col0, #T_0c53e_row3_col0, #T_0c53e_row4_col0 {\n",
       "  white-space: pre-wrap;\n",
       "}\n",
       "</style>\n",
       "<table id=\"T_0c53e\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th class=\"blank level0\" >&nbsp;</th>\n",
       "      <th id=\"T_0c53e_level0_col0\" class=\"col_heading level0 col0\" >Value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th id=\"T_0c53e_level0_row0\" class=\"row_heading level0 row0\" >Decision Type</th>\n",
       "      <td id=\"T_0c53e_row0_col0\" class=\"data row0 col0\" >approved</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_0c53e_level0_row1\" class=\"row_heading level0 row1\" >Application Type</th>\n",
       "      <td id=\"T_0c53e_row1_col0\" class=\"data row1 col0\" >NDA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_0c53e_level0_row2\" class=\"row_heading level0 row2\" >Drug Name</th>\n",
       "      <td id=\"T_0c53e_row2_col0\" class=\"data row2 col0\" >SKYCLARYS® (omaveloxolone)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_0c53e_level0_row3\" class=\"row_heading level0 row3\" >Indication</th>\n",
       "      <td id=\"T_0c53e_row3_col0\" class=\"data row3 col0\" >Friedreich’s ataxia</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_0c53e_level0_row4\" class=\"row_heading level0 row4\" >Notes</th>\n",
       "      <td id=\"T_0c53e_row4_col0\" class=\"data row4 col0\" >SKYCLARYS® is the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. The commercial launch is underway, and over 1,000 patient start forms have been submitted. European regulatory review is ongoing, and the drug has Orphan Drug designation in Europe.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n"
      ],
      "text/plain": [
       "<pandas.io.formats.style.Styler at 0x15a436f90>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<style type=\"text/css\">\n",
       "#T_61c9c_row0_col0, #T_61c9c_row1_col0, #T_61c9c_row2_col0, #T_61c9c_row3_col0, #T_61c9c_row4_col0 {\n",
       "  white-space: pre-wrap;\n",
       "}\n",
       "</style>\n",
       "<table id=\"T_61c9c\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th class=\"blank level0\" >&nbsp;</th>\n",
       "      <th id=\"T_61c9c_level0_col0\" class=\"col_heading level0 col0\" >Value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th id=\"T_61c9c_level0_row0\" class=\"row_heading level0 row0\" >Decision Type</th>\n",
       "      <td id=\"T_61c9c_row0_col0\" class=\"data row0 col0\" >approved</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_61c9c_level0_row1\" class=\"row_heading level0 row1\" >Application Type</th>\n",
       "      <td id=\"T_61c9c_row1_col0\" class=\"data row1 col0\" >NDA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_61c9c_level0_row2\" class=\"row_heading level0 row2\" >Drug Name</th>\n",
       "      <td id=\"T_61c9c_row2_col0\" class=\"data row2 col0\" >SKYCLARYS (omaveloxolone)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_61c9c_level0_row3\" class=\"row_heading level0 row3\" >Indication</th>\n",
       "      <td id=\"T_61c9c_row3_col0\" class=\"data row3 col0\" >Friedreich’s ataxia in adults and adolescents aged 16 years and older</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_61c9c_level0_row4\" class=\"row_heading level0 row4\" >Notes</th>\n",
       "      <td id=\"T_61c9c_row4_col0\" class=\"data row4 col0\" >SKYCLARYS (omaveloxolone) received FDA approval for the treatment of Friedreich’s ataxia in the U.S. The drug is also under review by the European Medicines Agency (EMA) and has received Orphan Drug designation in Europe for the same indication.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n"
      ],
      "text/plain": [
       "<pandas.io.formats.style.Styler at 0x159b52930>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<style type=\"text/css\">\n",
       "#T_1ab47_row0_col0, #T_1ab47_row1_col0, #T_1ab47_row2_col0, #T_1ab47_row3_col0, #T_1ab47_row4_col0 {\n",
       "  white-space: pre-wrap;\n",
       "}\n",
       "</style>\n",
       "<table id=\"T_1ab47\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th class=\"blank level0\" >&nbsp;</th>\n",
       "      <th id=\"T_1ab47_level0_col0\" class=\"col_heading level0 col0\" >Value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th id=\"T_1ab47_level0_row0\" class=\"row_heading level0 row0\" >Decision Type</th>\n",
       "      <td id=\"T_1ab47_row0_col0\" class=\"data row0 col0\" >approved</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_1ab47_level0_row1\" class=\"row_heading level0 row1\" >Application Type</th>\n",
       "      <td id=\"T_1ab47_row1_col0\" class=\"data row1 col0\" >NDA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_1ab47_level0_row2\" class=\"row_heading level0 row2\" >Drug Name</th>\n",
       "      <td id=\"T_1ab47_row2_col0\" class=\"data row2 col0\" >SKYCLARYS (omaveloxone)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_1ab47_level0_row3\" class=\"row_heading level0 row3\" >Indication</th>\n",
       "      <td id=\"T_1ab47_row3_col0\" class=\"data row3 col0\" >Friedreich's Ataxia</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_1ab47_level0_row4\" class=\"row_heading level0 row4\" >Notes</th>\n",
       "      <td id=\"T_1ab47_row4_col0\" class=\"data row4 col0\" >SKYCLARYS is the first and only FDA-approved treatment for Friedreich's Ataxia in the US, offering a clinically meaningful benefit in slowing disease progression and improving functional abilities. The US launch began in June 2023, and a Marketing Authorization Application (MAA) is under review in the EU. The product is indicated for patients older than 16 years old, with exclusivity expected through the late 2030s. SKYCLARYS is an oral, once-daily therapy with a well-characterized safety and tolerability profile.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n"
      ],
      "text/plain": [
       "<pandas.io.formats.style.Styler at 0x159b526f0>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "📢 Ticker: EDIT\n",
      "\n",
      "🗂️ EDIT — program_announcement — 2025\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<style type=\"text/css\">\n",
       "#T_67165_row0_col0, #T_67165_row1_col0, #T_67165_row2_col0, #T_67165_row3_col0, #T_67165_row4_col0, #T_67165_row5_col0, #T_67165_row6_col0 {\n",
       "  white-space: pre-wrap;\n",
       "}\n",
       "</style>\n",
       "<table id=\"T_67165\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th class=\"blank level0\" >&nbsp;</th>\n",
       "      <th id=\"T_67165_level0_col0\" class=\"col_heading level0 col0\" >Value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th id=\"T_67165_level0_row0\" class=\"row_heading level0 row0\" >Program Name</th>\n",
       "      <td id=\"T_67165_row0_col0\" class=\"data row0 col0\" >In vivo HSC-tLNP HBG1/2 Promoter Editing Program</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_67165_level0_row1\" class=\"row_heading level0 row1\" >Indication</th>\n",
       "      <td id=\"T_67165_row1_col0\" class=\"data row1 col0\" >Sickle cell disease and beta thalassemia</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_67165_level0_row2\" class=\"row_heading level0 row2\" >Platform</th>\n",
       "      <td id=\"T_67165_row2_col0\" class=\"data row2 col0\" >Proprietary targeted lipid nanoparticle (tLNP) delivery with AsCas12a gene editing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_67165_level0_row3\" class=\"row_heading level0 row3\" >Development Stage</th>\n",
       "      <td id=\"T_67165_row3_col0\" class=\"data row3 col0\" >Preclinical (non-human primate studies)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_67165_level0_row4\" class=\"row_heading level0 row4\" >Milestone</th>\n",
       "      <td id=\"T_67165_row4_col0\" class=\"data row4 col0\" >Achieved 58% mean HBG1/2 promoter editing in HSCs at five months post single dose in NHPs, exceeding therapeutic threshold</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_67165_level0_row5\" class=\"row_heading level0 row5\" >Partnership Info</th>\n",
       "      <td id=\"T_67165_row5_col0\" class=\"data row5 col0\" ></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_67165_level0_row6\" class=\"row_heading level0 row6\" >Timeline Estimate</th>\n",
       "      <td id=\"T_67165_row6_col0\" class=\"data row6 col0\" >Further development ongoing; data presented at EHA 2025 Congress</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n"
      ],
      "text/plain": [
       "<pandas.io.formats.style.Styler at 0x133550f50>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "🗂️ EDIT — program_announcement — 2023\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<style type=\"text/css\">\n",
       "#T_2585b_row0_col0, #T_2585b_row1_col0, #T_2585b_row2_col0, #T_2585b_row3_col0, #T_2585b_row4_col0, #T_2585b_row5_col0, #T_2585b_row6_col0 {\n",
       "  white-space: pre-wrap;\n",
       "}\n",
       "</style>\n",
       "<table id=\"T_2585b\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th class=\"blank level0\" >&nbsp;</th>\n",
       "      <th id=\"T_2585b_level0_col0\" class=\"col_heading level0 col0\" >Value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th id=\"T_2585b_level0_row0\" class=\"row_heading level0 row0\" >Program Name</th>\n",
       "      <td id=\"T_2585b_row0_col0\" class=\"data row0 col0\" >Non-exclusive Cas9 License Agreement for CASGEVY™ (exagamglogene autotemcel)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_2585b_level0_row1\" class=\"row_heading level0 row1\" >Indication</th>\n",
       "      <td id=\"T_2585b_row1_col0\" class=\"data row1 col0\" >Sickle cell disease and beta thalassemia</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_2585b_level0_row2\" class=\"row_heading level0 row2\" >Platform</th>\n",
       "      <td id=\"T_2585b_row2_col0\" class=\"data row2 col0\" >CRISPR/Cas9 gene editing technology</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_2585b_level0_row3\" class=\"row_heading level0 row3\" >Development Stage</th>\n",
       "      <td id=\"T_2585b_row3_col0\" class=\"data row3 col0\" >Commercial (CASGEVY™ is an approved therapy)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_2585b_level0_row4\" class=\"row_heading level0 row4\" >Milestone</th>\n",
       "      <td id=\"T_2585b_row4_col0\" class=\"data row4 col0\" >Vertex Pharmaceuticals obtained a non-exclusive license for Cas9 for ex vivo gene editing medicines targeting BCL11A, including CASGEVY™</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_2585b_level0_row5\" class=\"row_heading level0 row5\" >Partnership Info</th>\n",
       "      <td id=\"T_2585b_row5_col0\" class=\"data row5 col0\" >Vertex Pharmaceuticals entered into a non-exclusive license agreement with Editas Medicine for Cas9 technology. Editas is the exclusive licensee of certain CRISPR patent estates from Harvard, Broad Institute, MIT, and Rockefeller University.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_2585b_level0_row6\" class=\"row_heading level0 row6\" >Timeline Estimate</th>\n",
       "      <td id=\"T_2585b_row6_col0\" class=\"data row6 col0\" >Agreement announced December 13, 2023; extends Editas Medicine's cash runway into 2026</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n"
      ],
      "text/plain": [
       "<pandas.io.formats.style.Styler at 0x159b68fb0>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "🗂️ EDIT — clinical_results — 2025\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<style type=\"text/css\">\n",
       "#T_c316c_row0_col0, #T_c316c_row1_col0, #T_c316c_row2_col0, #T_c316c_row3_col0, #T_c316c_row4_col0, #T_c316c_row5_col0 {\n",
       "  white-space: pre-wrap;\n",
       "}\n",
       "</style>\n",
       "<table id=\"T_c316c\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th class=\"blank level0\" >&nbsp;</th>\n",
       "      <th id=\"T_c316c_level0_col0\" class=\"col_heading level0 col0\" >Value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th id=\"T_c316c_level0_row0\" class=\"row_heading level0 row0\" >Trial Phase</th>\n",
       "      <td id=\"T_c316c_row0_col0\" class=\"data row0 col0\" >Preclinical</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_c316c_level0_row1\" class=\"row_heading level0 row1\" >Drug Name</th>\n",
       "      <td id=\"T_c316c_row1_col0\" class=\"data row1 col0\" >Editas Medicine's in vivo HSC gene editing program (using proprietary tLNP and AsCas12a)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_c316c_level0_row2\" class=\"row_heading level0 row2\" >Indication</th>\n",
       "      <td id=\"T_c316c_row2_col0\" class=\"data row2 col0\" >Sickle cell disease and beta thalassemia</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_c316c_level0_row3\" class=\"row_heading level0 row3\" >Results Summary</th>\n",
       "      <td id=\"T_c316c_row3_col0\" class=\"data row3 col0\" >In humanized mice, a single dose achieved 48% HBG1/2 promoter editing in long-term HSCs. In non-human primates (NHPs), a single intravenous dose achieved up to 47% HBG1/2 editing in HSCs. Both exceeded the ≥25% editing threshold predicted for therapeutic benefit. The approach led to robust increases in fetal hemoglobin (HbF) and total hemoglobin (Hb) in clinical trials with the investigational medicine reni-cel.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_c316c_level0_row4\" class=\"row_heading level0 row4\" >Safety Profile</th>\n",
       "      <td id=\"T_c316c_row4_col0\" class=\"data row4 col0\" >Preliminary biodistribution data in NHPs showed significant de-targeting of the liver compared to standard LNPs, suggesting a potentially improved safety profile. No specific adverse events or tolerability findings were reported in these preclinical studies.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_c316c_level0_row5\" class=\"row_heading level0 row5\" >Next Steps</th>\n",
       "      <td id=\"T_c316c_row5_col0\" class=\"data row5 col0\" >Editas Medicine plans to translate these preclinical results to clinical development, aiming to address unmet needs in sickle cell disease and beta thalassemia.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n"
      ],
      "text/plain": [
       "<pandas.io.formats.style.Styler at 0x1335574a0>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<style type=\"text/css\">\n",
       "#T_ea6e0_row0_col0, #T_ea6e0_row1_col0, #T_ea6e0_row2_col0, #T_ea6e0_row3_col0, #T_ea6e0_row4_col0, #T_ea6e0_row5_col0 {\n",
       "  white-space: pre-wrap;\n",
       "}\n",
       "</style>\n",
       "<table id=\"T_ea6e0\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th class=\"blank level0\" >&nbsp;</th>\n",
       "      <th id=\"T_ea6e0_level0_col0\" class=\"col_heading level0 col0\" >Value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th id=\"T_ea6e0_level0_row0\" class=\"row_heading level0 row0\" >Trial Phase</th>\n",
       "      <td id=\"T_ea6e0_row0_col0\" class=\"data row0 col0\" >Preclinical (in vivo proof of concept in mice and non-human primates)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_ea6e0_level0_row1\" class=\"row_heading level0 row1\" >Drug Name</th>\n",
       "      <td id=\"T_ea6e0_row1_col0\" class=\"data row1 col0\" >Undisclosed CRISPR/Cas-based therapy (liver target)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_ea6e0_level0_row2\" class=\"row_heading level0 row2\" >Indication</th>\n",
       "      <td id=\"T_ea6e0_row2_col0\" class=\"data row2 col0\" >Undisclosed liver disease</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_ea6e0_level0_row3\" class=\"row_heading level0 row3\" >Results Summary</th>\n",
       "      <td id=\"T_ea6e0_row3_col0\" class=\"data row3 col0\" >In vivo CRISPR editing using lipid nanoparticles (LNPs) achieved ~70% maximal liver editing of the target gene in a disease-specific mouse model, resulting in robust target protein upregulation and >80% reduction in a clinically relevant disease biomarker. In cynomolgus monkey hepatocytes, >50% target gene editing and >15-fold protein upregulation were observed.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_ea6e0_level0_row4\" class=\"row_heading level0 row4\" >Safety Profile</th>\n",
       "      <td id=\"T_ea6e0_row4_col0\" class=\"data row4 col0\" >No specific safety or tolerability findings were disclosed in this update.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_ea6e0_level0_row5\" class=\"row_heading level0 row5\" >Next Steps</th>\n",
       "      <td id=\"T_ea6e0_row5_col0\" class=\"data row5 col0\" >Editas Medicine plans to share additional data, including the disease target and development candidate, later in 2025, with further presentations scheduled at upcoming scientific conferences.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n"
      ],
      "text/plain": [
       "<pandas.io.formats.style.Styler at 0x158455850>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "🗂️ EDIT — clinical_results — 2023\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<style type=\"text/css\">\n",
       "#T_b2761_row0_col0, #T_b2761_row1_col0, #T_b2761_row2_col0, #T_b2761_row3_col0, #T_b2761_row4_col0, #T_b2761_row5_col0 {\n",
       "  white-space: pre-wrap;\n",
       "}\n",
       "</style>\n",
       "<table id=\"T_b2761\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th class=\"blank level0\" >&nbsp;</th>\n",
       "      <th id=\"T_b2761_level0_col0\" class=\"col_heading level0 col0\" >Value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th id=\"T_b2761_level0_row0\" class=\"row_heading level0 row0\" >Trial Phase</th>\n",
       "      <td id=\"T_b2761_row0_col0\" class=\"data row0 col0\" >Phase 1/2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_b2761_level0_row1\" class=\"row_heading level0 row1\" >Drug Name</th>\n",
       "      <td id=\"T_b2761_row1_col0\" class=\"data row1 col0\" >renizgamglogene autogedtemcel (reni-cel), formerly EDIT-301</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_b2761_level0_row2\" class=\"row_heading level0 row2\" >Indication</th>\n",
       "      <td id=\"T_b2761_row2_col0\" class=\"data row2 col0\" >Severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_b2761_level0_row3\" class=\"row_heading level0 row3\" >Results Summary</th>\n",
       "      <td id=\"T_b2761_row3_col0\" class=\"data row3 col0\" >In the RUBY trial for severe SCD (n=11), all treated patients are free of vaso-occlusive events (VOEs) post-infusion. All RUBY patients with ≥5 months follow-up have achieved and maintained normal hemoglobin levels and fetal hemoglobin levels >40%. In the EdiTHAL trial for TDT (n=6), all patients demonstrated early and robust increases in total hemoglobin, surpassing the transfusion independence threshold of 9 g/dL. The results support early, robust correction of anemia and sustained increases in fetal hemoglobin in both indications.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_b2761_level0_row4\" class=\"row_heading level0 row4\" >Safety Profile</th>\n",
       "      <td id=\"T_b2761_row4_col0\" class=\"data row4 col0\" >Reni-cel was well-tolerated in both trials (n=17), with a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant. No serious adverse events related to reni-cel treatment have been reported.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_b2761_level0_row5\" class=\"row_heading level0 row5\" >Next Steps</th>\n",
       "      <td id=\"T_b2761_row5_col0\" class=\"data row5 col0\" >The company plans to dose additional patients and provide further clinical updates on the RUBY and EdiTHAL trials in mid-2024.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n"
      ],
      "text/plain": [
       "<pandas.io.formats.style.Styler at 0x133550f50>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<style type=\"text/css\">\n",
       "#T_1682f_row0_col0, #T_1682f_row1_col0, #T_1682f_row2_col0, #T_1682f_row3_col0, #T_1682f_row4_col0, #T_1682f_row5_col0 {\n",
       "  white-space: pre-wrap;\n",
       "}\n",
       "</style>\n",
       "<table id=\"T_1682f\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th class=\"blank level0\" >&nbsp;</th>\n",
       "      <th id=\"T_1682f_level0_col0\" class=\"col_heading level0 col0\" >Value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th id=\"T_1682f_level0_row0\" class=\"row_heading level0 row0\" >Trial Phase</th>\n",
       "      <td id=\"T_1682f_row0_col0\" class=\"data row0 col0\" >Phase 1/2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_1682f_level0_row1\" class=\"row_heading level0 row1\" >Drug Name</th>\n",
       "      <td id=\"T_1682f_row1_col0\" class=\"data row1 col0\" >EDIT-301</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_1682f_level0_row2\" class=\"row_heading level0 row2\" >Indication</th>\n",
       "      <td id=\"T_1682f_row2_col0\" class=\"data row2 col0\" >Severe sickle cell disease (RUBY trial) and transfusion-dependent beta thalassemia (EdiTHAL trial)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_1682f_level0_row3\" class=\"row_heading level0 row3\" >Results Summary</th>\n",
       "      <td id=\"T_1682f_row3_col0\" class=\"data row3 col0\" >In the RUBY trial, the first four patients with sickle cell disease treated with EDIT-301 showed normalization of total hemoglobin and sustained increases in fetal hemoglobin (>40%) at 5 months, maintained at 10 and 6 months for the first two patients. All four RUBY patients are free of vaso-occlusive events since infusion. In the EdiTHAL trial, the first patient with transfusion-dependent beta thalassemia achieved successful neutrophil and platelet engraftment and a fetal hemoglobin fraction of 34.9% (4 g/dL of total hemoglobin) at 1.5 months post-treatment, resembling the RUBY patients' responses.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_1682f_level0_row4\" class=\"row_heading level0 row4\" >Safety Profile</th>\n",
       "      <td id=\"T_1682f_row4_col0\" class=\"data row4 col0\" >EDIT-301 was well-tolerated in both trials. No serious adverse events occurred after infusion, and no adverse events were related to EDIT-301. All patients demonstrated successful neutrophil and platelet engraftment. The safety profile was consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_1682f_level0_row5\" class=\"row_heading level0 row5\" >Next Steps</th>\n",
       "      <td id=\"T_1682f_row5_col0\" class=\"data row5 col0\" >Editas Medicine plans to dose 20 RUBY patients by year-end and expects to present further clinical updates from the RUBY and EdiTHAL trials later in the year.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n"
      ],
      "text/plain": [
       "<pandas.io.formats.style.Styler at 0x133553290>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "🗂️ EDIT — clinical_results — 2024\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<style type=\"text/css\">\n",
       "#T_9b262_row0_col0, #T_9b262_row1_col0, #T_9b262_row2_col0, #T_9b262_row3_col0, #T_9b262_row4_col0, #T_9b262_row5_col0 {\n",
       "  white-space: pre-wrap;\n",
       "}\n",
       "</style>\n",
       "<table id=\"T_9b262\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th class=\"blank level0\" >&nbsp;</th>\n",
       "      <th id=\"T_9b262_level0_col0\" class=\"col_heading level0 col0\" >Value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th id=\"T_9b262_level0_row0\" class=\"row_heading level0 row0\" >Trial Phase</th>\n",
       "      <td id=\"T_9b262_row0_col0\" class=\"data row0 col0\" >Phase 1/2/3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_9b262_level0_row1\" class=\"row_heading level0 row1\" >Drug Name</th>\n",
       "      <td id=\"T_9b262_row1_col0\" class=\"data row1 col0\" >renizgamglogene autogedtemcel (reni-cel; formerly EDIT-301)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_9b262_level0_row2\" class=\"row_heading level0 row2\" >Indication</th>\n",
       "      <td id=\"T_9b262_row2_col0\" class=\"data row2 col0\" >severe sickle cell disease (SCD)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_9b262_level0_row3\" class=\"row_heading level0 row3\" >Results Summary</th>\n",
       "      <td id=\"T_9b262_row3_col0\" class=\"data row3 col0\" >In the RUBY trial (N=28), 27 of 28 patients treated with reni-cel were free of vaso-occlusive events (VOEs) post-infusion. Patients showed early normalization of total hemoglobin (mean increased from 9.8 g/dL at baseline to 13.8 g/dL at Month 6) and rapid, sustained improvements in fetal hemoglobin (mean HbF 48.1% at Month 6, n=18). The mean percentage of F-cells was sustained at >90% from month 4 onward, and markers of hemolysis improved or normalized by Month 6. Clinically meaningful improvements were observed in pain, physical function, and social roles per patient-reported outcomes.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_9b262_level0_row4\" class=\"row_heading level0 row4\" >Safety Profile</th>\n",
       "      <td id=\"T_9b262_row4_col0\" class=\"data row4 col0\" >Reni-cel was well-tolerated with a safety profile consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell transplant. All evaluable patients (n=27) achieved successful engraftment (median neutrophil engraftment: 23 days; platelet: 25 days). Two serious adverse events possibly related to reni-cel were reported.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_9b262_level0_row5\" class=\"row_heading level0 row5\" >Next Steps</th>\n",
       "      <td id=\"T_9b262_row5_col0\" class=\"data row5 col0\" >The RUBY trial is ongoing, with continued follow-up of patients. Additional details are available on clinicaltrials.gov (NCT04853576).</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n"
      ],
      "text/plain": [
       "<pandas.io.formats.style.Styler at 0x133553290>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<style type=\"text/css\">\n",
       "#T_9fe55_row0_col0, #T_9fe55_row1_col0, #T_9fe55_row2_col0, #T_9fe55_row3_col0, #T_9fe55_row4_col0, #T_9fe55_row5_col0 {\n",
       "  white-space: pre-wrap;\n",
       "}\n",
       "</style>\n",
       "<table id=\"T_9fe55\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th class=\"blank level0\" >&nbsp;</th>\n",
       "      <th id=\"T_9fe55_level0_col0\" class=\"col_heading level0 col0\" >Value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th id=\"T_9fe55_level0_row0\" class=\"row_heading level0 row0\" >Trial Phase</th>\n",
       "      <td id=\"T_9fe55_row0_col0\" class=\"data row0 col0\" >Phase 1/2/3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_9fe55_level0_row1\" class=\"row_heading level0 row1\" >Drug Name</th>\n",
       "      <td id=\"T_9fe55_row1_col0\" class=\"data row1 col0\" >renizgamglogene autogedtemcel (reni-cel; formerly known as EDIT-301)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_9fe55_level0_row2\" class=\"row_heading level0 row2\" >Indication</th>\n",
       "      <td id=\"T_9fe55_row2_col0\" class=\"data row2 col0\" >severe sickle cell disease</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_9fe55_level0_row3\" class=\"row_heading level0 row3\" >Results Summary</th>\n",
       "      <td id=\"T_9fe55_row3_col0\" class=\"data row3 col0\" >In the RUBY trial, all 18 patients treated with reni-cel were free of vaso-occlusive events (VOEs) for up to 22.8 months of follow-up. Patients experienced early normalization of total hemoglobin (mean >14 g/dL) and rapid, sustained increases in fetal hemoglobin (mean HbF >40%). At 6 months, mean total Hb was 14.3 g/dL and mean HbF was 48.5%. The mean percentage of F-cells was sustained at >90% from month 4 onward, and mean corpuscular fetal hemoglobin (MCH-F) was above the anti-sickling threshold of 10 pg/F-cell by month 3. Markers of hemolysis were normalized or improved, and all patients showed sustained high levels of editing in the HBG1 and HBG2 promoter regions.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_9fe55_level0_row4\" class=\"row_heading level0 row4\" >Safety Profile</th>\n",
       "      <td id=\"T_9fe55_row4_col0\" class=\"data row4 col0\" >Reni-cel was well-tolerated with a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant. All patients demonstrated successful neutrophil and platelet engraftment (median 23 and 24 days, respectively). No serious adverse events related to reni-cel treatment were reported.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_9fe55_level0_row5\" class=\"row_heading level0 row5\" >Next Steps</th>\n",
       "      <td id=\"T_9fe55_row5_col0\" class=\"data row5 col0\" >Editas Medicine has completed adult cohort enrollment and opened the adolescent cohort in the RUBY trial. Additional clinical data from the RUBY and EdiTHAL trials are expected to be presented by year-end 2024.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n"
      ],
      "text/plain": [
       "<pandas.io.formats.style.Styler at 0x159857b00>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<style type=\"text/css\">\n",
       "#T_231c4_row0_col0, #T_231c4_row1_col0, #T_231c4_row2_col0, #T_231c4_row3_col0, #T_231c4_row4_col0, #T_231c4_row5_col0 {\n",
       "  white-space: pre-wrap;\n",
       "}\n",
       "</style>\n",
       "<table id=\"T_231c4\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th class=\"blank level0\" >&nbsp;</th>\n",
       "      <th id=\"T_231c4_level0_col0\" class=\"col_heading level0 col0\" >Value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th id=\"T_231c4_level0_row0\" class=\"row_heading level0 row0\" >Trial Phase</th>\n",
       "      <td id=\"T_231c4_row0_col0\" class=\"data row0 col0\" >Phase 1/2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_231c4_level0_row1\" class=\"row_heading level0 row1\" >Drug Name</th>\n",
       "      <td id=\"T_231c4_row1_col0\" class=\"data row1 col0\" >renizgamglogene autogedtemcel (reni-cel; formerly EDIT-301)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_231c4_level0_row2\" class=\"row_heading level0 row2\" >Indication</th>\n",
       "      <td id=\"T_231c4_row2_col0\" class=\"data row2 col0\" >transfusion-dependent beta thalassemia (TDT)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_231c4_level0_row3\" class=\"row_heading level0 row3\" >Results Summary</th>\n",
       "      <td id=\"T_231c4_row3_col0\" class=\"data row3 col0\" >All 7 patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-reni-cel infusion. For patients with ≥6 months follow-up, mean total hemoglobin at month 6 was 12.1 g/dL (SD 1.3) and mean fetal hemoglobin was 10.9 g/dL (SD 1.5), sustained at or above the transfusion threshold from 6 months onward. All patients showed sustained high levels of editing in the HBG1 and HBG2 promoter regions.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_231c4_level0_row4\" class=\"row_heading level0 row4\" >Safety Profile</th>\n",
       "      <td id=\"T_231c4_row4_col0\" class=\"data row4 col0\" >Reni-cel was well-tolerated with a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant. All patients demonstrated successful neutrophil (median 23 days) and platelet (median 38 days) engraftment. No serious adverse events related to reni-cel treatment were reported.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_231c4_level0_row5\" class=\"row_heading level0 row5\" >Next Steps</th>\n",
       "      <td id=\"T_231c4_row5_col0\" class=\"data row5 col0\" >Editas Medicine will continue to evaluate the effectiveness of reni-cel in the EdiTHAL trial and plans to present further clinical updates from both the EdiTHAL and RUBY trials by year-end 2024.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n"
      ],
      "text/plain": [
       "<pandas.io.formats.style.Styler at 0x133550f50>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "🗂️ EDIT — program_termination — 2024\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<style type=\"text/css\">\n",
       "#T_43d74_row0_col0, #T_43d74_row1_col0, #T_43d74_row2_col0, #T_43d74_row3_col0, #T_43d74_row4_col0, #T_43d74_row5_col0 {\n",
       "  white-space: pre-wrap;\n",
       "}\n",
       "</style>\n",
       "<table id=\"T_43d74\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th class=\"blank level0\" >&nbsp;</th>\n",
       "      <th id=\"T_43d74_level0_col0\" class=\"col_heading level0 col0\" >Value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th id=\"T_43d74_level0_row0\" class=\"row_heading level0 row0\" >Program Name</th>\n",
       "      <td id=\"T_43d74_row0_col0\" class=\"data row0 col0\" >reni-cel</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_43d74_level0_row1\" class=\"row_heading level0 row1\" >Indication</th>\n",
       "      <td id=\"T_43d74_row1_col0\" class=\"data row1 col0\" >sickle cell disease and beta thalassemia</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_43d74_level0_row2\" class=\"row_heading level0 row2\" >Development Stage</th>\n",
       "      <td id=\"T_43d74_row2_col0\" class=\"data row2 col0\" >clinical (RUBY and EdiTHAL trials)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_43d74_level0_row3\" class=\"row_heading level0 row3\" >Reason</th>\n",
       "      <td id=\"T_43d74_row3_col0\" class=\"data row3 col0\" >Extensive search did not yield a commercial partner</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_43d74_level0_row4\" class=\"row_heading level0 row4\" >Financial Impact</th>\n",
       "      <td id=\"T_43d74_row4_col0\" class=\"data row4 col0\" >Initiating cost savings measures and reduction in headcount to align workforce and resources to in vivo pipeline, extending cash runway into Q2 2027</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th id=\"T_43d74_level0_row5\" class=\"row_heading level0 row5\" >Strategic Notes</th>\n",
       "      <td id=\"T_43d74_row5_col0\" class=\"data row5 col0\" >Editas Medicine is transitioning to a fully in vivo gene editing company, focusing on in vivo CRISPR-edited medicines and discontinuing ex vivo programs like reni-cel. The company will work with clinical trial sites, regulators, and other parties to determine the path forward for patients enrolled in the RUBY and EdiTHAL trials.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n"
      ],
      "text/plain": [
       "<pandas.io.formats.style.Styler at 0x1335574a0>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "def camel_to_title(s):\n",
    "    return re.sub(r'(?<=[a-z])(?=[A-Z])', ' ', s).replace(\"_\", \" \").title()\n",
    "\n",
    "for ticker, df in results_by_ticker.items():\n",
    "    print(f\"\\n📢 Ticker: {ticker}\")\n",
    "    \n",
    "    for event_type, row in df.iterrows():\n",
    "        for year, detail in row.items():\n",
    "            if not isinstance(detail, str) or not detail.strip():\n",
    "                continue\n",
    "\n",
    "            print(f\"\\n🗂️ {ticker} — {event_type} — {year}\")\n",
    "\n",
    "            try:\n",
    "                # Split by delimiter and parse each event separately\n",
    "                event_blobs = [blob for blob in detail.split(\"\\n---\\n\") if blob.strip()]\n",
    "                for blob in event_blobs:\n",
    "                    parsed_detail = json.loads(blob)\n",
    "                    details = parsed_detail.get(\"eventDetails\", {})\n",
    "\n",
    "                    if isinstance(details, dict) and details:\n",
    "                        display(pd.DataFrame.from_dict(\n",
    "                            {camel_to_title(k): v for k, v in details.items()},\n",
    "                            orient=\"index\",\n",
    "                            columns=[\"Value\"]\n",
    "                        ).style.set_properties(**{'white-space': 'pre-wrap'}))\n",
    "                    else:\n",
    "                        print(f\"⚠️ No eventDetails in blob: {blob}\")\n",
    "            except json.JSONDecodeError as e:\n",
    "                print(f\"❌ JSON decode error for {event_type} in {year}: {e}\")\n",
    "            except Exception as e:\n",
    "                print(f\"❌ Failed to parse/display event for {event_type} in {year}: {e}\")\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
